Novavax (NVAX) Capital Expenditures (2010 - 2026)

For the trailing twelve months through Jun 30, 2026, Capital Expenditures at Novavax was $5.3 million, down 2.4% year-over-year; for FY2025, it came in at $5.56 million, down 57.4% from FY2024.

• Annual Capital Expenditures has declined for three consecutive years, with a five-year compound annual growth rate of -36.6% (FY2020 to FY2025).
• In prior years, Novavax's Capital Expenditures was $13.06 million in FY2024 (-75.7%), $53.77 million in FY2023 (-39.6%), $89.06 million in FY2022 (+63.4%) and $54.5 million in FY2021 (+0.1%).
• Quarterly Capital Expenditures has run from a low of $527,000 in Q2 2025 to a high of $24.63 million in Q3 2022 over five years.
• On a year-over-year basis, Capital Expenditures increased in two of the last eight quarters, with an average decline of 41.4%.
• The strongest year-over-year quarter for Capital Expenditures in the past five years was Q3 2022, with growth of 102.1%; the weakest was Q3 2024, with a decline of 92.4%.
• According to Business Quant data, Capital Expenditures for the three prior quarters was $1.27 million (Q1 2026), $2.08 million (Q4 2025) and $1.36 million (Q3 2025).